science glp 1 The Behind the Quest for a Non-Peptide Oral Weight Loss Drug | Office for Science and Society GLP-1 drugs are entering a

In a statement to CBS News Detroit, the company said it is ending coverage of GLP-1 drugs "for large group fully insured members beginning January 1, 2025, or on a group's 2025 health coverage renewal date." Additionally, the company said it will change prior authorization requirements for Saxenda, Wegovy and Zepbound beginning Aug

All of these moves are compound exercises, meaning they work multiple joints at a time

Ghergurovich et al

It is hoped that ongoing trials like SUMMIT, which is investigating tirzepatide in participants with HFpEF and obesity, will provide more evidence on incretin-based medications in HFpEF

This analysis is the first of its kind to show the most up-to-date 2023 prescription data